EUVIMEDEUVIMED entdecken
Crossref

Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery

Masaru Takenaka, Fumihiro Tanaka, Kenta Kajiyama, Takehiko Manabe, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Aya Nawata, Koji Kuroda

Surgery Today · 2024-10 · 54 (10) · 1146-1153

DOI: 10.1007/s00595-024-02811-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery Today, online erschienen am 14.03.2024. Verfasst von Masaru Takenaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. m-takenaka@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Salvage Therapy, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsSalvage TherapyLung NeoplasmsProtein Kinase InhibitorsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedTreatment OutcomeNeoplasm Recurrence, LocalSurvival RateAged, 80 and overTime FactorsAdultTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Immune checkpoint inhibitorLung cancerPathologic responseSalvage surgeryTyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. m-takenaka@med.uoeh-u.ac.jp.
  • Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Zitieren

APA

Takenaka, M., Tanaka, F., Kajiyama, K., Manabe, T., Yoshimatsu, K., Mori, M., Kanayama, M., Taira, A., Kuwata, T., Nawata, A., & Kuroda, K. (2024). Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery. Surgery Today, 54(10), 1146-1153. https://doi.org/10.1007/s00595-024-02811-3

Vancouver

Takenaka M, Tanaka F, Kajiyama K, Manabe T, Yoshimatsu K, Mori M, et al. Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery. Surgery Today. 2024;54(10):1146-1153. doi:10.1007/s00595-024-02811-3

BibTeX
@article{Takenaka2024,
  author = {Takenaka, Masaru and Tanaka, Fumihiro and Kajiyama, Kenta and Manabe, Takehiko and Yoshimatsu, Katsuma and Mori, Masataka and Kanayama, Masatoshi and Taira, Akihiro and Kuwata, Taiji and Nawata, Aya and Kuroda, Koji},
  title = {Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery},
  journal = {Surgery Today},
  year = {2024},
  volume = {54},
  number = {10},
  pages = {1146--1153},
  doi = {10.1007/s00595-024-02811-3}
}
Kostenlos starten →